18-F-Flortaucipir
DrugRadioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
Other names: 11C-Pittsburgh Compound-B
NCT Number: NCT03821857
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
Interested in participating?
Request Info60 year and older
Female
Interventional
Phase 4
Mayo Clinic, Jacksonville, Florida, United States
The proposed project will enroll a total of 614 women.
Mayo Clinic Rochester Participants: Each women will have 2-3 clinic visits consisting of cognitive testing, tests of physical function, questionnaires, and a blood draw. All women will also undergo clinical neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451. All participants will have previously participated and will return by invitation only.
Mayo Clinic Jacksonville Participant: Only African American Women will be enrolled at this site. Each women will have 1-3 clinic visits consisting of physical function testing and neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Mayo Clinic Rochester-
Inclusion criteria
Exclusion criteria
Mayo Clinic Jacksonville-
Inclusion criteria
Exclusion criteria
Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
Other names: 11C-Pittsburgh Compound-B
Time frame: 1 day
Cortical 18F-Flortaucipir PET imaging measured once in each participant
Time frame: 1 day
Global cortical SUVR measured once in each participant
Contact information is provided by the study sponsor or research team.
Desirae Howe-Clayton, CRC
CONTACT
June Kendall-Thomas, CRC
CONTACT
Mayo Clinic
Other
Acronym: SEED-AD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06014424
Alzheimer Disease, Brain Diseases
Calgary, Alberta, Canada
View Trial DetailsNCT06847321
Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Phoenix, Arizona, United States
View Trial DetailsNCT06937229
Aberrant Motor Behavior in Dementia, Agitation
Chandler, Arizona, United States
View Trial DetailsNCT06862960
Alzheimer Disease, Brain Diseases
Fuzhou, Fujian, China
View Trial Details